News
KURA
8.65
-1.93%
-0.17
Analysts Are Bullish on Top Healthcare Stocks: Zimmer Biomet Holdings (ZBH), Kura Oncology (KURA)
TipRanks · 2d ago
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 2d ago
Kura Oncology (KURA) Receives a Buy from Barclays
TipRanks · 2d ago
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies
Benzinga · 3d ago
Kura Oncology falls despite trial success; rival Syndax gains
Seeking Alpha · 3d ago
Kura Oncology Price Target Maintained With a $28.00/Share by JMP Securities
Dow Jones · 3d ago
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target
Benzinga · 3d ago
Kura Oncology Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $36
Benzinga · 3d ago
Kura Oncology (KURA) Receives a Buy from Wedbush
TipRanks · 3d ago
Kura Oncology price target raised to $36 from $34 at Wedbush
TipRanks · 3d ago
KURA ONCOLOGY INC <KURA.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 3d ago
Kura Oncology drops 11% to $8.07 after leukemia update, BTIG downgrade
TipRanks · 3d ago
Scotiabank would buy Kura on weakness despite KOMET-001 uncertainty
TipRanks · 3d ago
Stifel Nicolaus Remains a Hold on Kura Oncology (KURA)
TipRanks · 3d ago
KURA ONCOLOGY INC <KURA.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $27
Reuters · 3d ago
TD Cowen Sticks to Its Buy Rating for Kura Oncology (KURA)
TipRanks · 3d ago
KURA ONCOLOGY INC <KURA.O>: WEDBUSH RAISES TARGET PRICE TO $36 FROM $34
Reuters · 3d ago
Kura Oncology downgraded to Neutral from Buy at BTIG
TipRanks · 3d ago
Kura Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
More
Webull provides a variety of real-time KURA stock news. You can receive the latest news about Kura Oncology Inc through multiple platforms. This information may help you make smarter investment decisions.
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.